Drugs / XCEL-MT-OSTEO-ALPHA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01605383 | May 2015 → Apr 2018 | avascular necrosis | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
| Phase 1/2 | NCT02230514 | Nov 2014 → Mar 2019 | — | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
| Phase 1/2 | NCT01552707 | Jul 2012 → May 2018 | lumbar disk degenerative disorder, spondylolisthesis | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XCEL-MT-OSTEO-ALPHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02230514 ↗ |
| Modality | Cell therapy | “"ex-vivo" expanded autologous mesenchymal stem cells” NCT01552707 ↗ |